Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Sarepta Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

61 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Salute
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Eventi
Mercato azionario
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Industria
Farmaceutica
Biotecnologia
Salute
Medicina - Varie
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Eventi
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
31/12/2026
Mercato azionario
Finanza
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
HIV, AIDS e malattie autoimmuni
Biotecnologia
Salute
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
14/11/2025
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/10/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Fonte
Sarepta Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0